Brazil Developing Triple-Combination Antiretroviral Drug
Brazil is in the final stages of testing atriple-combination antiretroviral drug, Orival Silveira, coordinator of thetreatment and assistance unit at the Ministry of Health's National Sexually Transmitted Diseases/AIDSProgram, said Wednesday, Xinhuanet reports. The three drugs used in the treatment-- zidovudine, lamivudine and nevirapine -- are being developed by theBrazil-based Oswaldo Cruz Foundation.
The triple-combination therapy will make it easier for HIV-positive people toadhere to their treatment regimens, Silveira said, adding that studies haveshown that treatment regimens with more than two pills daily are more difficultfor people to follow.
According to the health ministry, about 180,000 people inBrazilare undergoing antiretroviral treatment, which is subsidized fully by thegovernment (Xinhuanet, 12/20).
Reprinted with permission from kaisernetwork.org. You can view theentire Kaiser DailyHIV/AIDS Report, search the archives, and sign up for email delivery at kaisernetwork.org/email . The Kaiser Daily HIV/AIDS Report ispublished for kaisernetwork.org, a free service of The Henry J. Kaiser FamilyFoundation.